|
KLC1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.12030384968875E-11 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.36139988171635E-11 |
| Normal-vs-Stage2 |
1.008770E-04 |
| Normal-vs-Stage3 |
1.78709999998361E-06 |
| Normal-vs-Stage4 |
2.442500E-04 |
| Stage1-vs-Stage2 |
5.942400E-01 |
| Stage1-vs-Stage3 |
2.728000E-01 |
| Stage1-vs-Stage4 |
3.795800E-01 |
| Stage2-vs-Stage3 |
2.725800E-01 |
| Stage2-vs-Stage4 |
3.007000E-01 |
| Stage3-vs-Stage4 |
9.677600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.62000421358266E-11 |
| Normal-vs-AfricanAmerican |
1.591650E-04 |
| Normal-vs-Asian |
1.47690000007472E-07 |
| Caucasian-vs-AfricanAmerican |
2.639200E-01 |
| Caucasian-vs-Asian |
6.529800E-02 |
| AfricanAmerican-vs-Asian |
8.255000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.86800028170831E-10 |
| Normal-vs-Female |
1.63480007309147E-10 |
| Male-vs-Female |
2.601400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.66953126271119E-12 |
| Normal-vs-Age(41-60Yrs) |
9.04209995766792E-09 |
| Normal-vs-Age(61-80Yrs) |
2.41789999999575E-05 |
| Normal-vs-Age(81-100Yrs) |
1.154820E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.837780E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.372000E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.320420E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.965600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.882200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.400400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.432780E-04 |
| Classical-VS-Follicular |
4.893800E-02 |
| Classical-VS-Other |
8.914400E-01 |
| Classical-VS-Normal |
1.64901425847575E-12 |
| Tall-VS-Follicular |
4.956100E-02 |
| Tall-VS-Other |
2.270400E-02 |
| Tall-VS-Normal |
2.452200E-01 |
| Follicular-VS-Other |
4.740600E-01 |
| Follicular-VS-Normal |
8.412800E-04 |
| Other-VS-Normal |
4.842100E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.45999998149671E-09 |
| Normal-vs-N1 |
4.12120000004013E-06 |
| N0-vs-N1 |
9.282400E-01 |
|
|
